Recce Pharmaceuticals Ltd (ASX:RCE)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Research and Development of Pharmaceutical Drugs	7.51M	5.03M	4.37M	3.08M	1.64M
Research and Development of Pharmaceutical Drugs Growth	49.33%	15.19%	41.50%	88.41%	45.97%
Total	7.51M	5.03M	4.37M	3.08M	1.64M
Total Growth	49.33%	15.19%	41.50%	88.41%	45.97%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Australia	5.29M	3.83M	4.34M	2.84M	1.80M
Australia Growth	38.05%	-11.66%	53.07%	57.22%	125.84%
USA	1.65M	1.37M	58.47K	317.16K	134.17K
USA Growth	20.07%	2251.32%	-81.56%	136.38%	-61.45%
Unallocated	733.30K	-	-	-	-
UK	26.84K	26.81K	32.07K	23.01K	25.33K
UK Growth	0.12%	-16.41%	39.38%	-9.18%	3194.28%
Total	7.70M	5.24M	4.43M	3.18M	1.96M
Total Growth	47.14%	18.17%	39.53%	61.77%	71.09%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 18, 2026

Data Sources Report a data error